ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c

ArriVent BioPharma, Inc. (NASDAQ: AVBP) reported Q2 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92).

For earnings history and earnings-related data on ArriVent BioPharma, Inc. (AVBP) click here.

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Bernstein SocGen on Performance Food Group (PFGC): 'Not the quarter we were hoping for, but LT story intact'
• BMO Capital Reiterates Outperform Rating on Bunge (BG)